The global acne medication market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market include the rising prevalence of acne ailments globally. Sedentary lifestyle and increasing acceptance of skin care solutions are some other factors that are expected to accelerate the growth of the market. Availability and emergence of a broad variety of products such as lotions, creams, and gels constituting antibiotic agents and complimentary benefits pertaining to their use would increase the demand for acne medication products. Acne or acne vulgaris is a common skin condition majorly caused when the hair follicles are blocked due to excessive oil secretion, dirt, and dead skin cells. It is accompanied by pimples, whiteheads, blackheads, or scarring. Acne is categorized into two types, namely inflammatory and non-inflammatory acne. Acne treatment comprises the removal of dead skin cells, reducing sebum secretion, and eliminating the bacteria using drugs and medication.

Several factors such as smoking, hormonal changes, and excessive secretion of sebum, among others have resulted in a growing prevalence of acne. Moreover, according to a dermatology survey, the number of people affected due to acne is high in the westernized societies that comprise of North American region as well. The disease burden of acne supports the demand for acne medication throughout the North American region and has consistently grown in prevalence over the years. This continued expansion highlights unmet dermatologic needs for the disease and potential business opportunities for enhanced access and delivery of acne therapeutics. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions.

Recent Strategic Initiatives

    • In April 2021, Galderma announced the launch of Aklief used in acne treatment products in South Korea. This product selectively exploits the retinoid receptor-gamma present in the retinoic acid receptor (RAR) in the skin, thereby facilitating rapid and effective acne treatment. This strategic move will assist the company in expanding its business operations in South Korea.

    • In January 2021, GlaxoSmithKline announced a research collaboration with Eligo Bioscience. The Eligobiotics treatment for acne vulgaris incorporates novel CRISPR-based therapeutic technology. This strategic collaboration is expected to accelerate R&D activities, further offering a competitive advantage to the company.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- GlaxoSmithKline plc, Galderma S.A., and Bauch Health Companies, Inc., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Acne Medication Market Report by Segment

By Therapeutic Class

    • Retinoids

    • Antibiotics

    • Salicylic Acid

    • Benzoyl Peroxide

    • Others

By Formulation

    • Topical

    • Oral

Global Acne Medication Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa